How Should Prostate Specific Antigen Be Interpreted?

Overview

Journal Turk J Urol

Publisher Aves

Date 2015 Sep 2

PMID 26328106

Citations 7

Authors

Ali Atan

Ozer Guzel

Affiliations

Soon will be listed here.

Abstract

Since from its clinical introduction to the present time, measurement of serum prostate specific antigen (PSA) level is one of the most widely used tests in urology practice. Initially, the upper limit for PSA was 4 ng/mL, but today, a reduction for the upper limit is recommended to 2.5-3 ng/mL for patients between 60 and 65 years of age and younger. On the use of PSA as a screening test for prostate cancer, there are differences of opinion. However, it is a recommended test in the evaluation and monitoring of the risky group for prostate cancer. In conclusion PSA test should be performed at appropriate intervals for appropriate people with an appropriate age, after informing the patient about the test in detail.

Citing Articles

Nucleic Acid Aptamer-Based Biosensors: A Review.

Sequeira-Antunes B, Ferreira H Biomedicines. 2023; 11(12).

PMID: 38137422 PMC: 10741014. DOI: 10.3390/biomedicines11123201.

Prostatic Artery Embolization as a Treatment Option for Symptomatic Benign Prostatic Hyperplasia: Results from the Prospective Follow-Up Study in Lithuania.

Jankauskas T, Burzinskis E, Kaupas R, Basevicius A, Jievaltas M Medicina (Kaunas). 2023; 59(10).

PMID: 37893589 PMC: 10608601. DOI: 10.3390/medicina59101871.

Breviscapine Participates in the Progression of Prostate Cancer by Inhibiting ZFP91 Expression through Upregulation of MicroRNA-129-5p.

Yang J, Jin W, Zhang X, Chang P, Zheng D Evid Based Complement Alternat Med. 2021; 2021:1511607.

PMID: 34925523 PMC: 8674053. DOI: 10.1155/2021/1511607.

Multiparametric prostatic MRI should not be the only method to decide re-biopsy in the patients who had a negative prostatic biopsy.

Atan A Int Urol Nephrol. 2019; 51(10):1781-1782.

PMID: 31289982 DOI: 10.1007/s11255-019-02227-w.

Comparison of Ga-68 PSMA positron emission tomography/computerized tomography with Tc-99m MDP bone scan in prostate cancer patients.

Uslu-Besli L, Sager S, Akgun E, Asa S, Sahin O, Demirdag C Turk J Med Sci. 2019; 49(1):301-310.

PMID: 30761859 PMC: 7350868. DOI: 10.3906/sag-1807-4.

References

Mouraviev V, Madden J . Focal therapy for prostate cancer: pathologic basis. Curr Opin Urol. 2009; 19(2):161-7. DOI: 10.1097/MOU.0b013e328323f62b. View

Stamey T, Yang N, Hay A, McNeal J, Freiha F, Redwine E . Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317(15):909-16. DOI: 10.1056/NEJM198710083171501. View

Kawachi M, Bahnson R, Barry M, Busby J, Carroll P, Carter H . NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010; 8(2):240-62. DOI: 10.6004/jnccn.2010.0016. View

van Renterghem K, Van Koeveringe G, Achten R, Van Kerrebroeck P . A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies. Int Urol Nephrol. 2009; 42(1):29-38. PMC: 2844972. DOI: 10.1007/s11255-009-9596-z. View

Venderbos L, Roobol M . PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. Asian J Androl. 2011; 13(2):219-24. PMC: 3739214. DOI: 10.1038/aja.2010.180. View

Tuncel A, Aksut H, Agras K, Tekdogan U, Ener K, Atan A . Is serum prostate-specific antigen level affected by fasting and nonfasting?. Urology. 2005; 66(1):105-7. DOI: 10.1016/j.urology.2005.01.040. View

Atan A, Horn T, Hansen F, Jakobsen H, Hald T . Prostatic specific antigen and benign prostatic hyperplasia. Scand J Urol Nephrol. 1996; 30(4):299-302. DOI: 10.3109/00365599609182310. View

Mettlin C, Murphy G, Lee F, Littrup P, Chesley A, Babaian R . Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer. 1993; 72(5):1701-8. DOI: 10.1002/1097-0142(19930901)72:5<1701::aid-cncr2820720534>3.0.co;2-e. View

Kvale R, Auvinen A, Adami H, Klint A, Hernes E, Moller B . Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007; 99(24):1881-7. DOI: 10.1093/jnci/djm249. View

10.

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

11.

. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149(3):185-91. DOI: 10.7326/0003-4819-149-3-200808050-00008. View

12.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V . EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2010; 59(1):61-71. DOI: 10.1016/j.eururo.2010.10.039. View

13.

DAmico A, Whittington R, Malkowicz S, Fondurulia J, Chen M, Kaplan I . Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999; 17(1):168-72. DOI: 10.1200/JCO.1999.17.1.168. View

14.

Crawford E, Wilson S, McConnell J, Slawin K, Lieber M, Smith J . Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006; 175(4):1422-6. DOI: 10.1016/S0022-5347(05)00708-1. View

15.

Loeb S, Roehl K, Antenor J, Catalona W, Suarez B, Nadler R . Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006; 67(2):316-20. DOI: 10.1016/j.urology.2005.08.040. View

16.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

17.

Gjertson C, Albertsen P . Use and assessment of PSA in prostate cancer. Med Clin North Am. 2010; 95(1):191-200. DOI: 10.1016/j.mcna.2010.08.024. View

18.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

19.

Woolf S, Krist A . Shared decision making for prostate cancer screening: do patients or clinicians have a choice?. Arch Intern Med. 2009; 169(17):1557-9. DOI: 10.1001/archinternmed.2009.291. View

20.

van Leeuwen P, Connolly D, Gavin A, Roobol M, Black A, Bangma C . Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer. 2009; 46(2):377-83. DOI: 10.1016/j.ejca.2009.09.008. View